Validity of ADHD Subtypes Using Neuropsychological Measure - Full Text View

Sponsored by:	National Taiwan University Hospital
Information provided by:	National Taiwan University Hospital
ClinicalTrials.gov Identifier:	NCT00494819

Purpose

Background: Attention-Deficit/Hyperactivity Disorder (ADHD), characterized by inattention, hyperactivity, and impulsivity, is among the most common neuropsychiatric disorders worldwide (5-10% at school age) and in Taiwan (7.5%). The DSM-IV ADHD consists of three subtypes: predominantly Inattentive (ADHD-I), predominantly Hyperactivity/Impulsivity (ADHD-H), and Combined subtypes (ADHD-C). Although the DSM-IV field trials indicate that the current subtypes differ significantly on variables such as age of onset, gender ratio, and level of social and academic impairment, little has been addressed whether the DSM-IV subtypes differ neuropsychologically. Numerous researches have proved that stimulants (methylphenidate is the only stimulant in Taiwan) are the most effective medication in treating ADHD. Although the efficacy of methylphenidate on behavioral measures has been established in Taiwan, there is no information about neuropsychological measures.

Specific Aims:

to validate ADHD subtype by neuropsychological measures; and
to investigate the efficacy of methylphenidate on the improvement of executive functioning among children with ADHD.

Subjects and Methods: Participants will consist of 20 children with ADHD-C, 20 with ADHD-I, 10 with ADHD-H and 50 controls without ADHD in the age range of 7 to 10. The measures include the psychiatric interviews (Chinese K-SADS-E), neuropsychological tests (WISC-III, Cancellation Test, Digit Span, Trail Making Test, CPT, Circle Tracing Test), self-administered rating scale (SNAP-IV), and investigator administered assessment (CGI and Behavior Observation Ratings).

Anticipated Results: We anticipated that children in the ADHD and non-ADHD group will perform differently on the neuropsychological tests with more deficits in neuropsychological functions in the ADHD group. Also, we expected that methylphenidate will improve the performance on the neuropsychological tests and reduce the behavioral symptoms of ADHD children. Subtypes difference in the neuropsychological functions is also expected.

Condition
Attention-Deficit/Hyperactivity Disorder

Drug Information available for: Methylphenidate hydrochloride Methylphenidate

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case Control
Official Title:	Discriminate Validity of ADHD Subtypes Using Neuropsychological Test

Further study details as provided by National Taiwan University Hospital:

Biospecimen Retention: None Retained

Biospecimen Description:

Enrollment:	122
Study Start Date:	September 2005
Study Completion Date:	August 2006

Show Detailed Description

Eligibility

Ages Eligible for Study:	7 Years to 10 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

children with ADHD

Criteria

Inclusion Criteria:

patients who have clinically diagnosis of DSM-IV ADHD confirmed by the K-SADS-E, are aged 7-10, and have IQ > 80; and who and whose parents consent to this study

Exclusion Criteria:

if they have a history of brain injury or epilepsy, visual/auditory deficit or were diagnosed as having motor disorder, obsessive-compulsive disorder, mental retardation, mood disorders, pervasive developmental disorder, or schizophrenia

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00494819

Locations

Taiwan
National Taiwan Univeristy Hospital
Taipei, Taiwan, 10002

Sponsors and Collaborators

National Taiwan University Hospital

Investigators

Principal Investigator:

Susan Shur-Fen Gau, MD, PhD

National Taiwan University Hospital & College of Medicine

More Information

Publications indexed to this study:

Chiang M, Gau SS. Validation of attention-deficit-hyperactivity disorder subtypes among Taiwanese children using neuropsychological functioning. Aust N Z J Psychiatry. 2008 Jun;42(6):526-35.

Responsible Party:	National Taiwan University Hospital ( Susan Shur-Fen Gau )
Study ID Numbers:	9461700916, NSC 94-2815-C-002-177-H
Study First Received:	June 29, 2007
Last Updated:	September 1, 2008
ClinicalTrials.gov Identifier:	NCT00494819
Health Authority:	Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:

ADHD, subtype, methylphenidate, neuropsychological measures

Study placed in the following topic categories:

Signs and Symptoms
Attention Deficit Disorder with Hyperactivity
Mental Disorders
Mental Disorders Diagnosed in Childhood
Methylphenidate

Attention Deficit and Disruptive Behavior Disorders
Neurologic Manifestations
Hyperkinesis
Dyskinesias

Additional relevant MeSH terms:

Nervous System Diseases

ClinicalTrials.gov processed this record on January 16, 2009